The stockholder approvals clear the path for the Orphai Therapeutics acquisition and related change-of-control transactions. Monitor for the closing of the acquisition and the issuance of shares upon conversion of Series C Preferred Stock, which will determine the final ownership structure and potential Nasdaq listing implications.
Price Chart
Executive Summary
Quince Therapeutics stockholders approved the 2026 Equity Incentive Plan (initial reserve of 821,872 shares plus up to 1,377,845 returning shares) and the 2026 Employee Stock Purchase Plan (initial reserve of 142,045 shares) at a special meeting on October 6, 2026. Stockholders also approved an amendment to increase authorized common shares from 250,000,000 to 275,000,000 and approved the issuance of shares upon conversion of Series C Preferred Stock and related warrants, which may result in a change of control. These approvals are tied to the Orphai Therapeutics acquisition and governance overhaul flagged in the prior DEFA14A filing.
Key Facts
- Stockholders approved the 2026 Equity Incentive Plan with an initial reserve of 821,872 shares plus up to 1,377,845 returning shares from prior plans.
- Stockholders approved the 2026 Employee Stock Purchase Plan with an initial reserve of 142,045 shares.
- Stockholders approved an amendment to increase authorized common shares from 250,000,000 to 275,000,000.
- Proposal No.1 (issuance of shares upon conversion of Series C Preferred Stock and exercise of warrants, representing >20% of outstanding shares and potentially resulting in change of control) was approved with 180,550 votes for, 5,742 against, 671 abstained, and 261,531 broker non-votes.
- Proposal No.2 (issuance of shares upon conversion of Series C Preferred Stock and exercise of warrants under Nasdaq Listing Rule 5635(d)) was approved with 343,517 votes for, 5,759 against, 658 abstained, and 261,531 broker non-votes.
- Proposal No.3 (authorized share increase) was approved with 599,460 votes for, 11,184 against, 821 abstained.
- Proposal No.4 (2026 Plan) was approved with 298,960 votes for, 50,399 against, 575 abstained, and 261,531 broker non-votes.
- Proposal No.5 (2026 ESPP) was approved with 303,437 votes for, 45,864 against, 633 abstained, and 261,531 broker non-votes.
- The 2026 Plan and 2026 ESPP were previously approved by the Board on July 29, 2026 and July 30, 2026, respectively, subject to stockholder approval.
- The certificate of amendment to increase authorized shares was filed with the Delaware Secretary of State and became effective on October 6, 2026.
Financial Impact
Authorized common shares increased from 250,000,000 to 275,000,000; 2026 Plan authorizes up to 821,872 new shares plus up to 1,377,845 returning shares; 2026 ESPP authorizes 142,045 new shares. No financial figures were reported in the filing.
Risk Factors
- Potential significant dilution from the issuance of up to 821,872 new shares under the 2026 Plan plus up to 1,377,845 returning shares and 142,045 shares under the 2026 ESPP.
- Change of control risk: Proposal No.1 may result in a change of control of the company, which could lead to management and board changes beyond those already conditionally appointed.
- Execution risk related to the Orphai Therapeutics acquisition and integration.
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-415730 |
| Document: d115238dex102.htm | 0001193125-26-415730 |
| Document: d115238d8k.htm | 0001193125-26-415730 |
| Document: d115238dex31.htm | 0001193125-26-415730 |
| Document: 0001193125-26-415730-index-headers.html | 0001193125-26-415730 |
| Document: 0001193125-26-415730-index.html | 0001193125-26-415730 |
| Document: 0001193125-26-415730.txt | 0001193125-26-415730 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 144 | $32.83 | awaiting T+20 | — | $32.47 (−1.08%) |
Oct 19, 2026 8d ago | 3 | $40.27 | awaiting T+20 | — | $32.47 (−19.36%) |
Oct 19, 2026 8d ago | 3 | $40.27 | awaiting T+20 | — | $32.47 (−19.36%) |
Oct 19, 2026 8d ago | 3 | $40.27 | awaiting T+20 | — | $32.47 (−19.36%) |
Oct 19, 2026 8d ago | 3 | $40.27 | awaiting T+20 | — | $32.47 (−19.36%) |
Oct 19, 2026 8d ago | 3 | $40.27 | awaiting T+20 | — | $32.47 (−19.36%) |
Oct 19, 2026 8d ago | 8-K | $34.45 | awaiting T+20 | — | $32.47 (−5.73%) |
Oct 14, 2026 13d ago | SC 13G | $33.23 | awaiting T+20 | — | $32.47 (−2.27%) |
Oct 14, 2026 13d ago | SC 13G | $33.23 | awaiting T+20 | — | $32.47 (−2.27%) |
Oct 6, 2026 21d ago | 8-K | $26.72 | awaiting T+20 | — | $32.47 (+21.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers